DiaMedica Therapeutics is accelerating its breakthrough drug DM199, now advancing in pivotal trials for fetal growth restriction, preeclampsia, and acute ischemic stroke—conditions with no current treatments. With enrollment complete in key cohorts and promising data guiding next steps, the company is poised to deliver critical insights by early 2027, including an interim analysis of its stroke trial. Backed by strong finances and preclinical momentum, DiaMedica is positioning itself to transform outcomes for high-risk pregnancies and stroke patients through targeted vascular biology.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
